Clinical Trial: CP-481,715 Nickel Allergy Study.

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Ski

Brief Summary: To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Detailed Summary:
Sponsor: Pfizer

Current Primary Outcome: Effect of CP-481,715 on clinical response and cell infiltration after nickel challenge

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Pfizer

Dates:
Date Received: August 30, 2005
Date Started: September 2003
Date Completion: October 2005
Last Updated: July 23, 2006
Last Verified: November 2005